Strong Clinical Data for Breye Therapeutics' Lead Oral Asset Danegaptide Presented at Angiogenesis 2026 Symposium
Prof. Carl D. Regillo presented Phase 1b trial data for danegaptide in 24 patients with non-proliferative diabetic retinopathy (NPDR) and macular edema at the Angiogenesis, Exudation and Degeneration 2026 symposium on February 7, 2026.12
The oral treatment was well-tolerated, achieved targeted plasma levels, and showed retinal imaging data consistent with reductions in vascular leakage in more than half of patients, with statistically significant reductions in edema measures after 4 weeks.12
Danegaptide is a first-in-class oral small molecule that stabilizes vasculature and protects against retinal capillary breakdown caused by hyperglycemia.12
The data support advancing to a Phase 2 randomized trial assessing improvements in Diabetic Retinopathy Severity Scale (DRSS) scores; Breye is preparing and fundraising for this.123
Sources:
1. https://www.globenewswire.com/news-release/2026/02/09/3234282/0/en/Strong-clinical-data-for-Breye-Therapeutics-lead-oral-asset-danegaptide-presented-at-Angiogenesis-Exudation-and-Degeneration-2026-symposium.html
2. https://pharmatimes.com/news/strong-clinical-data-for-breye-lead-asset-danegaptide/